Effect of GRAPEX in treatment of COVID-19

Effect of Grapex on the alternations of clinical symptoms and laboratory finding on COVID19.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200921048783N1

Enrollment

Registered

2020-12-06

Start date

2021-01-08

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Patients receiving standard country protocol drugs with Grapex 200 mg twice a day until the patient's clinical symptoms improve . Intervention 2: Control group: P

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with covid19 by positive PCR test. Patients diagnosed with covid19 by positive CT scan evaluation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Time to clinical alternations defined as start of taking medication time to Discharge Time. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Medical record.	—

Secondary

Measure	Time frame
Complete Blood Count. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;C-reactive-protein. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;SER. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Creatinine. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Aspartate amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Alanine amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Prothrombin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Partial Thromboplastin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Cough. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Clinical observation and examination.;Level of consciousness. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Using the Glasgow Coma scale.;Arterial oxygen saturation. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Blood sample.;Blood pressure. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Clinical examination.;Level of serum sodium. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Level of serum potassium. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;BUN. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;INR. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blo	—

Measure

Time frame

Complete Blood Count. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;C-reactive-protein. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;SER. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Creatinine. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Aspartate amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Alanine amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Prothrombin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Partial Thromboplastin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Cough. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Clinical observation and examination.;Level of consciousness. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Using the Glasgow Coma scale.;Arterial oxygen saturation. Timepoint: The beginning of the study ,the seventh day, the fourteenth day. Method of measurement: Blood sample.;Blood pressure. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Clinical examination.;Level of serum sodium. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Level of serum potassium. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;BUN. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;INR. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blo

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Mojiri-Forushani

Abadan University of Medical Sciences

dr.mojiri@yahoo.com+98 61 5338 4004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026